|
APLS | Apellis Pharmaceuticals, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.18 |
| Leverage | 65.58% |
| Market Cap | $ 2.0B |
| PE | 88.12 |
| Dividend Yield | 0.00% |
| Profit | $ 23.2m |
| Margin | 2.32% |
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.